#1 Clinical Trials Search in Europe

N-Sulfoglucosamine Sulfohydrolase Fused To A Humanised Monoclonal Antibody Targeting Human Transferrin Receptor

A new drug called JR-441 is being tested in clinical trials for patients with a rare genetic disorder called Mucopolysaccharidosis Type IIIA (MPS IIIA). This drug is a special protein that combines an enzyme called N-sulfoglucosamine sulfohydrolase with an antibody that targets a specific receptor in the body. The trial aims to evaluate how safe and effective JR-441 is when given as weekly infusions to patients aged 1 to 18 years old with MPS IIIA.

Table of Contents

What is JR-441?

JR-441 is an innovative medication being developed to treat a rare genetic disorder called Mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo Syndrome Type A[1]. The technical name for this drug is “N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor.” This complex name describes how the medication is designed to work in the body.

To break it down:

  • N-sulfoglucosamine sulfohydrolase: This is an enzyme that is missing or defective in people with MPS IIIA.
  • Humanised monoclonal antibody: This is a type of protein that can target specific cells in the body.
  • Human transferrin receptor: This is a protein found on the surface of cells, including brain cells, that helps transport iron into the cells.

By combining these elements, JR-441 aims to deliver the missing enzyme to the cells that need it, including those in the brain[1].

What is MPS IIIA?

Mucopolysaccharidosis Type IIIA (MPS IIIA) is a rare genetic disorder that affects the body’s ability to break down certain complex sugar molecules[1]. People with MPS IIIA lack an enzyme called N-sulfoglucosamine sulfohydrolase (SGSH). This enzyme deficiency leads to the buildup of a substance called heparan sulfate in cells throughout the body, particularly in the brain.

The symptoms of MPS IIIA typically appear in early childhood and may include:

  • Developmental delays
  • Behavioral problems
  • Sleep disturbances
  • Progressive intellectual disability
  • Loss of previously acquired skills

Currently, there is no cure for MPS IIIA, which is why the development of treatments like JR-441 is so important[1].

How JR-441 Works

JR-441 is designed to work as an enzyme replacement therapy. Here’s how it aims to help patients with MPS IIIA:

  1. The medication is given through an intravenous infusion, which means it’s delivered directly into the bloodstream[1].
  2. The humanised monoclonal antibody part of JR-441 targets the transferrin receptor on cells, including those in the brain.
  3. This targeting helps the medication cross the blood-brain barrier, which is usually a challenge for many drugs.
  4. Once inside the cells, JR-441 provides the missing SGSH enzyme, which can then help break down the accumulated heparan sulfate.

By providing the missing enzyme, JR-441 aims to reduce the buildup of harmful substances in cells and potentially slow down or improve the symptoms of MPS IIIA[1].

Clinical Trial Details

JR-441 is currently being studied in a Phase I/II clinical trial. Here are some key details about the study[1]:

  • Trial Name: Phase I/II study of weekly infusions of JR-441 in patients with mucopolysaccharidosis type IIIA
  • Main Objective: To evaluate the safety and explore the efficacy of JR-441 in treating MPS IIIA patients
  • Treatment Schedule: Weekly infusions of JR-441
  • Study Duration: Up to 260 weeks (5 years)
  • Age Range: Patients aged 1 to 18 years old

Eligibility Criteria

To participate in the JR-441 clinical trial, patients must meet certain criteria. Some key inclusion criteria are[1]:

  • Confirmed diagnosis of MPS IIIA, including low SGSH enzyme activity and genetic testing
  • Age between 1 and 18 years at the time of enrollment
  • Minimum body weight of 10 kg
  • Medically stable condition

Some exclusion criteria include:

  • Previous gene therapy or successful stem cell transplantation
  • Pregnancy or breastfeeding
  • Recent participation in other clinical trials
  • Certain medical conditions that might interfere with the study

Safety and Efficacy Measures

The clinical trial will closely monitor several aspects to assess the safety and potential effectiveness of JR-441[1]:

Safety Measures:

  • Occurrence of adverse events (side effects)
  • Changes in laboratory tests (blood and urine tests)
  • Vital signs (heart rate, blood pressure, etc.)
  • Electrocardiogram (ECG) results
  • Infusion-related reactions

Efficacy Measures:

  • Changes in heparan sulfate levels in cerebrospinal fluid, blood, and urine
  • Cognitive function assessments
  • Adaptive behavior assessments

Potential Benefits and Risks

While JR-441 shows promise as a potential treatment for MPS IIIA, it’s important to understand that it is still in the experimental stage[1].

Potential Benefits:

  • Reduction in heparan sulfate buildup in cells
  • Possible improvement or stabilization of MPS IIIA symptoms
  • Contribution to the advancement of MPS IIIA treatment research

Potential Risks:

  • Infusion-related reactions
  • Unknown long-term side effects
  • Possibility that the treatment may not be effective for all patients

It’s crucial for patients and families considering participation in the JR-441 clinical trial to discuss the potential benefits and risks thoroughly with their healthcare providers[1].

Aspect Details
Drug Name JR-441
Drug Composition N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor
Condition Treated Mucopolysaccharidosis Type IIIA (MPS IIIA)
Trial Phase Phase I/II
Age Group 1 to 18 years old
Administration Method Weekly intravenous infusions
Primary Endpoints Safety assessments, including adverse events, laboratory tests, vital signs, and infusion-associated reactions
Secondary Endpoints Pharmacokinetics, changes in heparan sulfate levels, cognitive function, and adaptive behavior

FAQ

  • What is Mucopolysaccharidosis Type IIIA (MPS IIIA)? MPS IIIA is a rare genetic disorder where the body lacks an enzyme called N-sulfoglucosamine sulfohydrolase. This leads to the buildup of certain substances in the body, causing various health problems.
  • How is JR-441 given to patients in the trial? JR-441 is given as weekly infusions, which means the medication is delivered directly into the bloodstream through a vein.
  • What are the main goals of this clinical trial? The main goals are to evaluate the safety of JR-441 and explore how effective it is in treating patients with MPS IIIA.
  • Who can participate in this clinical trial? Patients aged 1 to 18 years old with a confirmed diagnosis of MPS IIIA and weighing at least 10 kg can potentially participate, subject to meeting other specific criteria.
  • What will researchers measure during the trial? Researchers will monitor for side effects, changes in laboratory tests, vital signs, and heart function. They will also measure the concentration of the drug in the blood and assess improvements in cognitive function and adaptive behavior.

Ongoing Clinical Trials on N-Sulfoglucosamine Sulfohydrolase Fused To A Humanised Monoclonal Antibody Targeting Human Transferrin Receptor

  • Study of Weekly Infusions of JR-441 for Patients with Mucopolysaccharidosis Type IIIA

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Mucopolysaccharidosis Type IIIA (MPS IIIA): A rare genetic disorder where the body lacks an enzyme called N-sulfoglucosamine sulfohydrolase, leading to the buildup of certain substances and causing various health problems.
  • N-sulfoglucosamine sulfohydrolase: An enzyme that is missing or deficient in patients with MPS IIIA. JR-441 aims to replace this enzyme.
  • Infusion: A method of delivering medication directly into the bloodstream through a vein.
  • Enzyme: A protein that helps speed up chemical reactions in the body.
  • Antibody: A protein produced by the immune system that can recognize and bind to specific targets in the body.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and eliminated.
  • Cognitive function: Mental abilities such as thinking, learning, and memory.
  • Adaptive behavior: Skills needed for daily living, such as communication, self-care, and social interactions.
  • Heparan sulfate: A substance that builds up in the body of patients with MPS IIIA, potentially causing harm.
  • Cerebrospinal fluid (CSF): The clear fluid that surrounds the brain and spinal cord.

References

  1. http://clinicaltrials.eu/trial/study-of-weekly-infusions-of-jr-441-for-patients-with-mucopolysaccharidosis-type-iiia/